Atomoxetine (Strattera) Use in Pregnancy and Lactation: Evidence‑Based Guidance

1. Safety During Pregnancy

Atomoxetine is not associated with an increased risk of major congenital malformations, including cardiac defects, based on several cohort studies (high‑quality observational data)【1】【2】【3】【4】.

A large, well‑controlled cohort found no increased risk of neurodevelopmental psychiatric disorders, visual or auditory impairment, epilepsy, seizures, or growth restriction in children whose mothers used atomoxetine during pregnancy (high‑quality observational evidence)【1】【2】【3】【5】.

Spontaneous abortion may be modestly increased, but confounding by the underlying ADHD cannot be excluded (moderate‑quality evidence)【1】【2】【3】【4】.
No evidence of higher rates of preeclampsia, preterm birth, or poor neonatal adaptation specifically linked to atomoxetine exposure (moderate‑quality evidence)【1】.

If atomoxetine does not severely impair daily functioning, a gradual discontinuation before conception can be considered (moderate‑quality guidance)【6】【7】【8】.
When the medication is essential for functioning, continue at the lowest effective dose, consider intermittent dosing, or discuss switching to another non‑stimulant (moderate‑quality guidance)【6】【7】【8】.
A comprehensive risk‑benefit discussion with the patient is recommended before any change in therapy (moderate‑quality guidance)【6】【7】【8】.

If atomoxetine is required for daily functioning, treatment should generally be maintained because documented maternal‑fetal risks are very low (high‑quality consensus)【6】【7】【9】【10】.
Maintain a well‑tolerated, effective dose or consider intermittent use after individualized risk‑benefit assessment (moderate‑quality guidance)【6】【7】【8】【10】.
Monitor pregnancy closely: fetal growth ultrasounds, blood pressure checks, and appropriate maternal weight gain (standard obstetric care)【6】【7】【8】【10】.

Switching to bupropion may be appropriate for patients with co‑occurring depression, acknowledging that bupropion is less efficacious for ADHD than stimulants (moderate‑quality guidance)【6】【7】【8】【9】【10】.
Non‑pharmacologic interventions (psycho‑education, CBT, mindfulness) can be trialed for mild‑to‑moderate ADHD (moderate‑quality guidance)【8】.

Caution is advised because no formal breastfeeding studies exist; pharmacokinetic data suggest atomoxetine can appear in human milk (theoretical risk)【1】【2】【3】.
Infants should be monitored for growth and developmental milestones when the mother continues atomoxetine while lactating (standard pediatric follow‑up)【6】【7】【8】【9】【10】.
If concern persists, timing of feeds or pumping to minimize infant exposure can be employed (practical recommendation)【6】【7】【8】【10】.

ADHD itself may pose pregnancy‑related risks (e.g., impaired maternal functioning) that can affect outcomes, underscoring the importance of individualized treatment decisions (moderate‑quality evidence)【6】【7】【8】【9】【10】.
2024 guidelines from the American Journal of Obstetrics and Gynecology conclude that documented medication risks are very low; therefore, treatment should not be discontinued when essential for daily functioning (high‑quality consensus)【6】【7】【9】【10】.
Overall risk elevation appears more linked to ADHD itself rather than atomoxetine exposure (moderate‑quality evidence)【6】【7】【9】【10】.